Latest news
ctDNA Is Becoming a Surveillance Policy, Not Just a Test
The phase III FIND trial suggests ctDNA-guided surveillance after curative-intent colorectal cancer surgery can identify recurrence earlier and increase the chance of curative-intent treatment. The science is promising. The implementation question is brutal: who gets watched closely enough to benefit?
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.